Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Tacrolimus 0.1% Ophthalmic Suspension in Vernal Keratoconjunctivitis
NCT00567918Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- May 2004
- Primary completion
- Jan 2008
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tacrolimus in Vernal Keratoconjunctivitis (VKC), sponsored by Astellas Pharma. Started May 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT00567918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567918.